Page last updated: 2024-09-05

sorafenib and Grippe

sorafenib has been researched along with Grippe in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barclay, W; Frise, R; Gravenstein, I; Herrmann, A; Imai-Matsushima, A; Karlas, A; Lesch, M; Luckner, M; Martin-Sancho, L; Meyer, M; Meyer, TF; Raftery, M; Schönrich, G; Sieben, C; Weege, F; Welke, RW	1
de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC	1

Trials

1 trial(s) available for sorafenib and Grippe

Article	Year
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination	2011

Article

Year

Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination

2011

Other Studies

1 other study(ies) available for sorafenib and Grippe

Article	Year
RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. PLoS pathogens, 2019, Volume: 15, Issue:3 Topics: A549 Cells; Active Transport, Cell Nucleus; Antiviral Agents; Host-Pathogen Interactions; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Orthomyxoviridae; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; RNA Interference; RNA Viruses; RNA, Small Interfering; Sorafenib; Urea; Virus Replication	2019

Article

Year

RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.

PLoS pathogens, 2019, Volume: 15, Issue:3

Topics: A549 Cells; Active Transport, Cell Nucleus; Antiviral Agents; Host-Pathogen Interactions; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Orthomyxoviridae; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; RNA Interference; RNA Viruses; RNA, Small Interfering; Sorafenib; Urea; Virus Replication

2019